Inhibition of nuclear factor-κB activation confers sensitivity to tumor necrosis factor-α by impairment of cell cycle progression in human glioma cells

Cancer Research

Volumn 59, Issue 17, 1999, Pages 4446-4452

  Otsuka, Goro ^a,b   Nagaya, Takashi ^a   Saito, Kiyoshi ^b   Mizuno, Masaaki ^b   Yoshida, Jun ^b   Seo, Hisao ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR GROWTH;

CELL CYCLE; DIMERIZATION; GLIOMA; HUMANS; NF-KAPPA B; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033199867     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Yoshida, J., Wakabayashi, T., Mizuno, M., Sugita, K., Yoshida, T., Hori, S., Mori, T., Sato, T., Karashima, A., Kurisu, K., Kiya, K., and Uozumi, T. Clinical effect of intra-arterial tumor necrosis factor-α for malignant glioma. J. Neurosurg., 77: 78-83, 1992.
2. Yoshida, J., Kajita, Y., Wakabayashi, T., and Sugita, K. Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with Interferon, ACNU and radiation. Acta Neurochir., 127: 55-59, 1994.
3. Shapiro, W. R., Green, S. B., Burger, P. C., Mahaley, M. J., Selker, R. G., VanGilder, J. C., Robertson, J. T., Ransohoff, J., Mealey, J. J., Strike, T. A., and Pistenmaa, D. A. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J. Neurosurg., 71: 1-9, 1989.
4. Kirby, S., Brothers, M., Irish, W., Florell, R., Macdonald, D., Schold, C., and Caimcross, G. Evaluating glioma therapies: modeling treatments and predicting outcomes. J. Natl. Cancer Inst., 87: 1884-1888, 1995.
5. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 72: 3666-3670, 1975.
6. Helson, L., Green, S., Carswell, E., and Old, L. J. Effect of tumour necrosis factor on cultured human melanoma cells. Nature (Lond), 258: 731-732, 1975.
7. Sugarman, B. J., Aggarwal, B. B., Hass, P. E., Figari, I. S., Palladino, M. J., and Shepard, H. M. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science (Washington DC), 230: 943-945, 1985.
8. Laster, S. M., Wood, J. G., and Gooding, L. R. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J. Immunol., 141: 2629-2634, 1988.
9. Rubin, B. Y., Smith, L. J., Hellermann, G. R., Lunn, R. M., Richardson, N. K., and Anderson, S. L. Correlation between the anticellular and DNA fragmenting activities of tumor necrosis factor. Cancer Res., 48: 6006-6010, 1988.
10. Wiedenmann, B., Reichardt, P., Rath, U., Theilmann, L., Schule, B., Ho, A. D., Schlick, E., Kempeni, J., Hunstein, W., and Kommereill, B. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J. Cancer Res. Clin. Oncol., 115: 189-192, 1989.
11. Creaven, P. J., Brenner, D. E., Cowens, J. W., Huben, R. P., Wolf, R. M., Takita, H., Arbuck, S. G., Razack, M. S., and Proefrock, A. D. A Phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother. Pharmacol., 23: 186-191, 1989.
12. Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M. Dissection of TNF-receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell, 87: 565-576, 1996.
13. Sen, R., and Baltimore, D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 46: 705-716, 1986.
14. Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van, A. D., and Miyamoto, S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev., 9; 2723-2735, 1995.
15. Baldwin, A. J. The NF-κB and IκB proteins: new discoveries and insights. Ann. Rev. Immunol., 14: 649-683, 1996.
16. Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., and Dorken, B. Constitutive nuclear factor-κB-RelA activation is required for proliferation and sur-vival of Hodgkin's disease tumor cells. J. Clin. Invest., 100: 2961-2969, 1997.
17. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the ReIA component of NF-κB. Nature (Lond.), 376: 167-170, 1995.
18. Van, A. D., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. Suppression of TNF-α-induced apoptosis by NF-κB. Science (Washington DC), 274: 787-789,1996.
19. Wang, C. Y., Mayo, M. W., and Baldwin, A. J. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Washington DC), 274: 784-787, 1996.
20. Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsura, M., Katz, D., FitzGerald, M. J., Rothstein, T. L., Sherr, D. H., and Sonenshein, G. E. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J., 15: 4682-4690, 1996.
21. Higuchi, M., and Aggarwal, B. B. Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies. J. Biol. Chem., 267: 20892-20899, 1992.
22. Nagaya, T., and Jameson, J. L. Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance. J. Biol. Chem., 268: 15766-15771, 1993.
23. Baeuerle, P. A., and Henkel, T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol., 12: 141-179, 1994.
24. Kikumori, T., Kambe, F., Nagaya, T., Imai, T., Funahashi, H., and Seo, H. Activation of transcriptionally active nuclear factor-κB by tumor necrosis factor-alpha and its inhibition by antioxidants in rat thyroid FRTL-5 cells. Endocrinology, 139: 1715-1722, 1998.
25. Ruben, S. M., Dillon, P. J., Schreck, R., Henkel, T., Chen, C. H., Maher, M., Baeuerle, P. A., and Rosen, C. A. Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science (Washington DC), 251: 1490-1493, 1991.
26. Sellins, K. S., and Cohen, J. J. Gene induction by -γ-irradiation leads to DNA fragmentation in lymphocytes. J. Immunol., 139: 3199-3206, 1987.
27. Vermes, I., Haanen, C., Steffens, N. H., and Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods, 184: 39-51, 1995.
28. Schmitz, M. L., and Baeuerle, P. A. The p65 subunit is responsible for the strong transcription activating potential of NF-KB. EMBO J., 10: 3805-3817, 1991.
29. Beg, A. A., and Baltimore, D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science (Washington DC), 274: 782-784, 1996.
30. Clemens, J. A., Stephenson, D. T., Smalstig, E. B., Dixon, E. P., and Little, S. P. Global ischemia activates nuclear factor-κB in forebrain neurons of rats. Stroke, 28: 1073-1080, 1997.
31. Grilli, M., Pizzi, M., Memo, M., and Spano, P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-γB activation. Science (Washington DC), 274: 1383-1385, 1996.
32. Cai, Z., Komer, M., Tarantino, N., and Chouaib, S. 1κB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-κB activation but not tumor necrosis factor-α-induced apoptosis. J. Biol. Chem., 272: 96-101, 1997.
33. Jeoung, D. I., Tang, B., and Sonenberg, M. Effects of tumor necrosis factor-α on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J. Biol. Chem., 270: 18367-18373, 1995.
34. Shiohara, M., Gombart, A. F., Berman, J. D., Koike, K., Komiyama, A., and Koeffler, H. P. Cytostatic effect of TNFa on cancer cells is independent of p21WAFl. Oncogene, 15: 1605-1609, 1997.
35. 1 transition in mouse fibroblasts. Mol. Cell. Biol., 11: 4943-4951, 1991.
36. Das, K. C., and White, C. W. Activation of NF-κB by antineoplastic agents. Role of protein kinase C. J. Biol. Chem., 272: 14914-14920, 1997.